Research
Hormonal
Dual GLP-1/GIP agonist tirzepatide (10-15 mg/week) produces superior weight loss (approx. 20.2%) compared to semaglutide (2.4 mg/week, approx. 13.7%) in patients with obesity.
If you are struggling with obesity and other treatments have failed, ask your doctor about tirzepatide. It is a weekly injection that targets hunger hormones and has been shown to produce greater weight loss than semaglutide. Be prepared for potential stomach issues, which usually improve over time, especially if the dose is increased slowly.
StrongSupportsVERY_HIGH confidence
SURMOUNT-5 (2025): comparison: tirzepatide 10–15 mg vs semaglutide 2.4 mg, tirzepatide: –20.2% vs semaglutide: –13.7% (P < 0.001)
Why this rating
Based on Phase III randomized clinical trials (SURMOUNT-5).
Source
GLP-1 and GIP analogues in the treatment of obesity – Current State of Knowledge
Marta Grycan et al. · Biuletyn Głównej Biblioteki Lekarskiej · 2025
DOI 10.2478/bgbl-2025-0015
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1 agonists (specifically semaglutide and liraglutide) reduce Major Adverse Cardiovascular Events (MACE) by 12-26% in patients with type 2 diabetes and obesity.Strong
- Discontinuation of GLP-1/GIP agonist therapy leads to significant weight regain (approx. 2/3 of lost weight within 1-2 years), necessitating chronic use.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →